Amanote Research
Register
Sign In
The Food and Drug Administration’s Revolving Door
C&EN Global Enterprise
doi 10.1021/cen-09747-cover3
Full Text
Open PDF
Abstract
Available in
full text
Date
December 2, 2019
Authors
Unknown
Publisher
American Chemical Society (ACS)
Related search
Revisiting the Revolving Door
UN Department of Economic and Social Affairs (DESA) Working Papers
David Oliver: The Revolving Door to the NHS Lobby
British Medical Journal
Medicine
The Value of the Revolving Door: Political Appointees and the Stock Market
SSRN Electronic Journal
Food and Drug Administration’s Regulatory Shift on Direct-To-Consumer Genetic Tests for Cancer Risk
Cancer
Cancer Research
Oncology
A Comparison of Results of the US Food and Drug Administration’s Mini-Sentinel Program With Randomized Clinical Trials
JAMA Internal Medicine
Internal Medicine
Beyond the Revolving Door: Long-Term Lived Experience of Eating Disorders and Specialist Service Provision
Qualitative Health Research
Environmental
Public Health
Occupational Health
Who Walks Through the Revolving Door? Examining the Lobbying Activity of Former Members of Congress
Interest Groups and Advocacy
Sociology
Political Science
Can We Close the Revolving Door?: Recidivism vs. Employment of Ex-Offenders in the U.S.
An Evaluation of US Food and Drug Administration’s Program to Register HIV Drugs for Use in Resource-Constrained Settings
JAMA network open
Medicine
